JP Morgan Chase
RUBY

JP Morgan Chase’s Rubius Therapeutics, Inc RUBY Stock Holding History

JP Morgan Chase’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,196
Closed – – 7481
2022
Q4 		$0 Sell
2,196
-3,561
-62% -$973 ﹤0.01% 7252
2022
Q3 		$2K Sell
5,757
-551,112
-99% -$413K ﹤0.01% 6288
2022
Q2 		$474K Sell
556,869
-2,507,630
-82% -$4.21M ﹤0.01% 4600
2022
Q1 		$16.9M Sell
3,064,499
-97,017
-3% -$616K ﹤0.01% 1915
2021
Q4 		$30.6M Buy
3,161,516
+708,647
+29% +$9.83M ﹤0.01% 1486
2021
Q3 		$43.9M Buy
2,452,869
+91,781
+4% +$2M 0.01% 1249
2021
Q2 		$57.6M Buy
2,361,088
+98,589
+4% +$2.47M 0.01% 1152
2021
Q1 		$60M Sell
2,262,499
-324,623
-13% -$4.74M 0.01% 1083
2020
Q4 		$19.6M Buy
2,587,122
+278,848
+12% +$1.66M ﹤0.01% 1626
2020
Q3 		$11.7M Buy
2,308,274
+250,237
+12% +$1.33M ﹤0.01% 1922
2020
Q2 		$12.3M Buy
2,058,037
+884,463
+75% +$5.22M ﹤0.01% 1732
2020
Q1 		$5.22M Buy
1,173,574
+381,422
+48% +$2.83M ﹤0.01% 2227
2019
Q4 		$7.53M Buy
792,152
+49,819
+7% +$482K ﹤0.01% 2363
2019
Q3 		$5.83M Buy
742,333
+65,145
+10% +$759K ﹤0.01% 2579
2019
Q2 		$10.1M Buy
677,188
+72,519
+12% +$1.17M ﹤0.01% 2101
2019
Q1 		$10.9M Buy
604,669
+273,272
+82% +$4.19M ﹤0.01% 1974
2018
Q4 		$5.33M Buy
331,397
+18,421
+6% +$336K ﹤0.01% 2531
2018
Q3 		$7.51M Buy
+312,976
New +$7.16M ﹤0.01% 2434

Other funds holding RUBY

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

JP Morgan Chase's RUBY Position: Q1 2023 in Review

JP Morgan Chase sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 2,196 shares.

JP Morgan Chase first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $60M in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • JP Morgan Chase reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • JP Morgan Chase sold 2,196 Rubius Therapeutics, Inc shares in Q1 2023.
  • JP Morgan Chase first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • JP Morgan Chase's Rubius Therapeutics, Inc position peaked at $60M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.